



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 64989

Title: HE Negative by IHC(1+) but Positive by FISH after Neoadjuvant
Chemotherapy in Invasive Breast Cancer: A Case Report and Review

Reviewer's code: 05830723

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: United States

Author's Country/Territory: China

Manuscript submission date: 2021-02-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-02 22:50

Reviewer performed review: 2021-05-15 17:59

Review time: 12 Days and 19 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The authors reported a case showing the disparity on IHC and FISH testing results on HER2 post neoadjuvant chemotherapy. The manuscript is well-written and easy to understand. Specific comments are: (1) The authors mentioned that only ~2% of the patients show the discrepancy on HER2 IHC and FISH testing which referred to a study by Shui R et al. Although the sample size is 12,467, it mainly represents one ethnicity. How about this phenomenon (discrepancy on IHC and FISH) in other populations around the world? (2) Luminal A breast cancer is ER and/or PR positive , HER2 negative and low Ki-67 level. Is Ki-67 level tested along with ER, PR and HER2 pre- and post-NACT? (3) The magnification of FISH figures should be indicated in the figure legend. It is preferred to use arrows to point out positive foci representing HER2 amplification. (4) Is lumpectomy a better medical term to describe "breast-conserving surgery"? (5) Is there any follow-up testing for this case? What's your opinions on the possible, post-NACT changes of the HER2 signature over time?